Proactive Investors - Run By Investors For Investors

Genus upgraded by Kepler as African swine fever concerns abate

Kepler Chevreux analyst said that in the short term, it regards African swine fever as a manageable one-off that Genus can cope with
Genus upgraded by Kepler as African swine fever concerns abate
Genus’s share price is 25% off the peak it reached last July

Genus PLC (LON:GNS) has been upgraded to a ‘buy’ from a ‘hold’ rating by broker Kepler Chevreux who believes the fall in the animal genetics company’s share price on the back of fears over the outbreak of African swine fever has been overdone.

Genus’s share price is 25% off the peak it reached last July, triggered by the outbreak of African swine fever (ASF) in China.

READ: Genus sounds note of caution over African swine fever and trade disputes

China accounts for 10% of earnings of Genus’ porcine division and for 15% of group earnings.

“In the short term, we regard African swine fever as a manageable one-off. Our base case assumes a 25% cut in PIC’s volume and EBIT in China in 2019E,” Kepler analysts said in a note to clients.

“We see the 25% decline in the share price as overdone and upgrade our rating from ‘hold’ to ‘buy’,” they added.

Kepler believes the fever will likely cause a modest slowdown in volume growth and a 1% cut in 2019 forecast earnings per share (EPS). In a worst-case scenario, another 5% cut in 2019E EPS might be needed, they add.

Shares in Genus were 8.2% up at 2,504.0p in late morning trade.

View full GNS profile View Profile

Genus Timeline

Newswire
February 16 2015

Related Articles

bacteria
September 25 2018
A decision on whether or not Motif can start marketing its next-generation antibiotic in the US is due by mid-February
scientist in lab
September 11 2018
The phase 1b trial of Silence’s lead candidate, SLN124, a treatment for a rare blood disorder, is scheduled to begin in the second half of 2019
Cyrptocurrencies
June 27 2018
Lancor Scientific is aiming to carry out an initial coin offering by issuing Medici, a new currency based on Ethereum to help Tumour Trace to fund further development

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use